Literature DB >> 18270248

De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR.

Johnthomas Kang1, Stephen J Huddleston, Joanne M Fraser, Alexander Khoruts.   

Abstract

Although regulatory CD4+CD25+ forkhead box p3+ (Foxp3+) T cells (Tregs) are generally thought to arise in the thymus as a separate lineage of CD4 T cells, they can also be induced de novo in the periphery. Peripheral development of Tregs from naïve T cells is favored by low-intensity activation and absence of inflammation. We show here that absence of CD28 costimulation results in a modest decrease in activation of naïve, antigen-specific CD4 T cells under noninflammatory conditions and benefits their initial Foxp3 induction. However, expression of Foxp3 following T cell activation without CD28 costimulation remains sensitive to the antigen dose. Furthermore, basal CD28 costimulation is critical for survival of the induced Foxp3+ CD4 T cells, and their accumulation is abrogated in the absence of CD28. In contrast, pharmacologic blockade of mammalian target of rapamycin enhances lasting induction of Tregs, irrespective of the initial antigen dose used to activate the antigen-specific T cells. This finding may have important practical, clinical implication in development of tolerance protocols.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270248     DOI: 10.1189/jlb.1207851

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  62 in total

Review 1.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

2.  Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo.

Authors:  N M Rogers; S Kireta; P T H Coates
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

3.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 4.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

Review 5.  The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.

Authors:  Jonathan D Powell; Greg M Delgoffe
Journal:  Immunity       Date:  2010-09-24       Impact factor: 31.745

Review 6.  Role of Metabolism in the Immunobiology of Regulatory T Cells.

Authors:  Mario Galgani; Veronica De Rosa; Antonio La Cava; Giuseppe Matarese
Journal:  J Immunol       Date:  2016-10-01       Impact factor: 5.422

7.  Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells.

Authors:  Caroline E von Allmen; Nicole Schmitz; Monika Bauer; Heather J Hinton; Michael O Kurrer; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Tim Sparwasser; Roger R Beerli; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

8.  High TCR stimuli prevent induced regulatory T cell differentiation in a NF-κB-dependent manner.

Authors:  Luciana L Molinero; Michelle L Miller; César Evaristo; Maria-Luisa Alegre
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

Review 9.  mTOR: taking cues from the immune microenvironment.

Authors:  Greg M Delgoffe; Jonathan D Powell
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

10.  Activated mammalian target of rapamycin is associated with T regulatory cell insufficiency in nasal polyps.

Authors:  Geng Xu; Jiahong Xia; Xiaoyang Hua; Han Zhou; Chuanzhao Yu; Zheng Liu; Kemin Cai; Jianbo Shi; Huabin Li
Journal:  Respir Res       Date:  2009-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.